SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Rhythm Pharmaceuticals, Inc. (RYTM) News

Follow Rhythm Pharmaceuticals, Inc. (RYTM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 36 public stories across 15 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol RYTM Asset equity Sector Markets 90 days 30 Last 112.53 Updated Nov 05, 2026, 09:07 AM UTC Open live news feed Open RYTM chart & news
M AstraZeneca Makes About $10 Billion Offer for Rhythm Pharmaceuticals AstraZeneca has made an offer of about $10 billion for Rhythm Pharmaceuticals, MT Newswires reports. MNA | Nov 05, 2026, 09:07 AM UTC M AstraZeneca reportedly makes an offer for Rhythm Pharmaceuticals According to some sources, AstraZeneca has made an offer for the obesity-drug maker. MNA | Nov 04, 2026, 10:56 PM UTC M AstraZeneca Offers for Rhythm, Sources Say AstraZeneca made an offer for Rhythm, according to sources. MNA | Nov 04, 2026, 10:20 PM UTC M AstraZeneca Made Roughly $10B Offer for Rhythm Pharmaceuticals, Sources Say The Wall Street Journal reports, citing sources, that AstraZeneca made an offer of roughly $10 billion for Rhythm Pharmaceuticals. MNA | Nov 04, 2026, 09:00 PM UTC L RYTM: trading halted on Nasdaq — volatility pause (3:57 PM ET) Nasdaq halted trading in RYTM (volatility pause) at 3:57 PM ET. EQUITY | Nov 04, 2026, 08:57 PM UTC M RYTM Reports Fiscal Q3 Net Loss The company reported a fiscal Q3 2026 net loss attributable to shareholders, up 1.83% year over year, and basic EPS of -2.18. EQUITY | Nov 04, 2026, 06:28 AM UTC M Rhythm Pharmaceuticals Reports 3Q 2026 Revenue of $92.13 Million Revenue rose 79.6% year over year to $92.13 million. Net loss narrowed to $42.35 million from $54.28 million, and diluted loss per share improved to $0.61 from $0.82. EARNINGS | Nov 03, 2026, 09:14 PM UTC M Rhythm Pharmaceuticals Shares Fall 8.7% After Q3 Net Loss Rhythm Pharmaceuticals reported a net loss for the third quarter, and its shares fell 8.7%. EQUITY | Nov 03, 2026, 02:33 PM UTC M Rhythm Pharmaceuticals Q3 Loss Narrows, Revenue Rises; Shares Down Pre-Bell EQUITY | Nov 03, 2026, 01:13 PM UTC M Rhythm Pharmaceuticals Q3 Net Loss Narrows 22% to $41.37 Million EQUITY | Nov 03, 2026, 12:20 PM UTC M Rhythm Pharmaceuticals Reports Third-Quarter 2026 Results and Business Update Rhythm Pharmaceuticals reported strong U.S. launch momentum for IMCIVREE for acquired hypothalamic obesity. EQUITY | Nov 03, 2026, 12:02 PM UTC M Rhythm Amends Bivamelagon Royalty Structure, Secures $750 Million Financing EQUITY | Nov 03, 2026, 09:05 AM UTC M Rhythm Amends LG Chem Deal, Secures Up to $750 Million Financing Rhythm Pharmaceuticals amended its licensing agreement with LG Chem for investigational oral therapy bivamelagon and secured access to up to $750 million in financing to support the program and its broader portfolio. EQUITY | Nov 03, 2026, 06:31 AM UTC M Rhythm Secures $750 Million Term-Loan Facility Rhythm secured a $750 million term-loan facility led by KKR's HealthCare Royalty in partnership with Blackstone. EQUITY | Nov 03, 2026, 03:06 AM UTC M Rhythm Pharmaceuticals, LG Chem Amend Bivamelagon License Agreement The amendment sets royalties at 1% of global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718. Rhythm will pay LG Chem an additional $350 million over four years and secured a $750 milli EQUITY | Nov 03, 2026, 03:02 AM UTC M Rhythm Pharmaceuticals Secures $750 Million Term-Loan Facility The facility is led by KKR Healthcare Royalty and Blackstone. EQUITY | Nov 03, 2026, 03:00 AM UTC L Rhythm Pharmaceuticals Obtains Financing Led by KKR and Blackstone The financing is led by KKR’s HealthCare Royalty alongside Blackstone. EQUITY | Nov 03, 2026, 03:00 AM UTC M Rhythm Pharmaceuticals Secures Up to $750 Million Term Loan The term loan is led by KKR’s HealthCare Royalty with Blackstone. EQUITY | Nov 03, 2026, 03:00 AM UTC L Rhythm launches IMCIVREE in Japan for acquired hypothalamic obesity Rhythm Pharmaceuticals announced the commercial launch of IMCIVREE (setmelanotide) in Japan for patients with acquired hypothalamic obesity. EQUITY | Oct 13, 2026, 11:30 PM UTC L Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm NEW YORK, Sept. 28, 2026 // -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) breached their fiduciary duties to NEWS | Sep 28, 2026, 01:10 PM UTC M Health Canada approves Rhythm’s IMCIVREE for weight management RYTM - Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity REGULATION | Sep 22, 2026, 12:04 PM UTC L Rhythm Pharmaceuticals Coverage Assumed by Leerink Partners at Outperform Ratings actions from Benzinga: GMT) Rhythm Pharmaceuticals Price Target Announced at $133.00/Share by Leerink PartnersRatings actions from Benzinga NEWS | Sep 14, 2026, 09:09 PM UTC L Rhythm Pharmaceuticals presents real-world setmelanotide BMI and risk results Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France. Phase 3 analyses demonstrated improvements across multip EQUITY | Sep 10, 2026, 12:04 PM UTC L RYTM - Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting - Click For Rele RYTM - Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting EQUITY | Sep 10, 2026, 12:00 PM UTC L RYTM: HO launch gains traction, Prader-Willi trials advance, and financials support robust investment The business is advancing three rare disease pillars, with a strong HO launch showing broad prescriber engagement and favorable payer trends. Prader-Willi development is progressing with positive phase II data and strate EQUITY | Sep 09, 2026, 08:51 PM UTC L RYTM early HO launch momentum and Prader-Willi plans drive growth The conference cited strong early momentum in the HO launch, broad prescriber engagement and favorable payer dynamics. It also highlighted Prader-Willi syndrome as a major strategic focus, with robust Phase II data and p MACRO | Sep 09, 2026, 08:13 PM UTC L Deutsche Bank initiates Rhythm Pharmaceuticals at Hold Deutsche Bank initiated coverage of Rhythm Pharmaceuticals with a Hold rating. EQUITY | Aug 28, 2026, 01:09 PM UTC L RYTM - Imcivree Approval In Japan Represents Meaningful Growth opportunity @ MSCO RYTM - Imcivree Approval In Japan Represents Meaningful Growth opportunity @ MSCO EQUITY | Aug 24, 2026, 12:56 PM UTC M Rhythm Pharmaceuticals wins Japan approval for IMCIVREE in acquired hypothalamic obesity Rhythm Pharmaceuticals says Japan’s MHLW approved IMCIVREE (setmelanotide) for patients with acquired hypothalamic obesity in Japan. REGULATION | Aug 24, 2026, 12:01 PM UTC M Rhythm wins Japan approval for Imcivree in acquired HO Rhythm Pharmaceuticals says Japan's MHLW approves Imcivree (setmelanotide) for patients with acquired hypothalamic obesity, with launch in Japan expected by end of 2026 pending pricing. EQUITY | Aug 24, 2026, 12:00 PM UTC L Rhythm Pharmaceuticals appoints Manher (AJ) Joshi as CMO Rhythm Pharmaceuticals (RYTM) announces the appointment of Manher (AJ) Joshi as Chief Medical Officer. EQUITY | Aug 17, 2026, 12:01 PM UTC L RYTM - Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update RYTM - Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update EARNINGS | Aug 04, 2026, 01:33 PM UTC H Rhythm Pharmaceuticals Reports Positive Efficacy Signal Rhythm Pharmaceuticals shows positive efficacy in phase 2 trial EQUITY | Aug 04, 2026, 10:55 AM UTC L RYTM Initiated Overweight W/$145.00 PT at JPMorgan RYTM Initiated Overweight W/$145.00 PT at JPMorgan EQUITY | Jul 27, 2026, 12:08 PM UTC L Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: O Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: OVERWEIGHT @ JPM CLH ITG: BUY @ BAC ARLO WSM: OVERWEIGHT @ Piper ADUR: BUY @ ROTH EQUITY | Jul 27, 2026, 11:09 AM UTC L RYTM Reiterate Market Outperform, $155 PT following HO survey for Imcivree @ Citizens RYTM Reiterate Market Outperform, $155 PT following HO survey for Imcivree @ Citizens EQUITY | Jul 14, 2026, 11:37 AM UTC